Clinical Chemistry Link to Randox Laboratories Web Site
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
QUICK SEARCH:   [advanced]


     

Clinical Chemistry 49: 1940-1942, 2003; 10.1373/clinchem.2003.018911
This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Submit an electronic Letter to
the Editor about this paper
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in ISI Web of Science
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via ISI Web of Science (14)
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Ghilardi, G.
Right arrow Articles by Scorza, R.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Ghilardi, G.
Right arrow Articles by Scorza, R.
Related Collections
Right arrow Molecular Diagnostics and Genetics
Right arrow Cancer Diagnostics (since 2002)
(Clinical Chemistry. 2003;49:1940-1942.)
© 2003 American Association for Clinical Chemistry, Inc.

Technical Briefs

Colorectal Carcinoma Susceptibility and Metastases Are Associated with Matrix Metalloproteinase-7 Promoter Polymorphisms

Giorgio Ghilardi1,a, Maria Luisa Biondi2, Maddalena Erario2, Emma Guagnellini2 and Roberto Scorza1

1 Dipartimento MCO, Clinica Chirurgica Generale, Università degli Studi di Milano, Polo S. Paolo, Via A. Di Rudinì 8, I-20142 Milan, Italy;
2 Laboratorio di Chimica Clinica e Microbiologia, Ospedale S. Paolo, Polo Universitario, Via A. Di Rudinì 8, I-20142 Milan, Italy

aauthor for correspondence: fax 39-02-8137613, e-mail giorgio.ghilardi@unimi.it

The first 300 words of the full text of this article appear below.

Tumor invasion and metastasis are important aspects of tumor progression, and the formation of tumor metastasis is a principal contributing factor to cancer morbidity and mortality (1). Basal membrane and extracellular matrix represent two physical barriers to malignant invasion: their degradation by matrix metalloproteinases (MMPs) plays a key role in tumor progression and metastatic spread (2)(3).

MMP expression in tumors is regulated in a paracrine manner by growth factors and cytokines secreted by tumor-infiltrating inflammatory cells as well as by tumor or stromal cells. Recent studies have suggested continuous cross-talk between tumor cells, stromal cells, and inflammatory cells during the invasion process (1)(2)(4)(5). Expression of most MMPs is usually low in tissues and is induced when remodeling of extracellular matrix is required. MMP gene expression is primarily regulated at the transcriptional level, but there is also evidence of modulation of mRNA stability in response to growth factor and cytokines (2)(6).

Several lines of evidence indicate a significant association between variations in MMP genes and susceptibility to cancer. The promoter region of inducible MMP genes (i.e., MMP1 and MMP3) shows remarkable conservation of regulatory elements, and their expression is induced by growth factors, cytokines, and other environmental factors, such as contact with extracellular matrix (7)(8)(9).

Recently, a naturally occurring sequence variation in the human MMP1 gene promoter was reported (10). Many studies have demonstrated the correlation between the 2G allele and several malignant tumors with different histogenetic origins (11)(12)(13)(14)(15). Recently, our group demonstrated a correlation between the MMP3 polymorphism and breast cancer (16).

Matrilysin (MMP7) is a protease with broad substrate specificity, . . . [Full Text of this Article]




The following articles in journals at HighWire Press have cited this article:


Home page
 Cancer Epidemiol. Biomarkers Prev.Home page
W. Qiu, G. Zhou, Y. Zhai, X. Zhang, W. Xie, H. Zhang, H. Yang, L. Zhi, X. Yuan, X. Zhang, et al.
No Association of MMP-7, MMP-8, and MMP-21 Polymorphisms with the Risk of Hepatocellular Carcinoma in a Chinese Population
Cancer Epidemiol. Biomarkers Prev., September 1, 2008; 17(9): 2514 - 2518.
[Abstract] [Full Text] [PDF]

Home page
 Cancer Res.Home page
A. Beeghly-Fadiel, J.-R. Long, Y.-T. Gao, C. Li, S. Qu, Q. Cai, Y. Zheng, Z.-X. Ruan, S. E. Levy, S. L. Deming, et al.
Common MMP-7 Polymorphisms and Breast Cancer Susceptibility: A Multistage Study of Association and Functionality
Cancer Res., August 1, 2008; 68(15): 6453 - 6459.
[Abstract] [Full Text] [PDF]

Home page
 Mol Hum ReprodHome page
K. Shan, Z. Lian-Fu, D. Hui, G. Wei, W. Na, J. Xia, and L. Yan
Polymorphisms in the promoter regions of the matrix metalloproteinases-7, -9 and the risk of endometriosis and adenomyosis in China
Mol. Hum. Reprod., January 1, 2006; 12(1): 35 - 39.
[Abstract] [Full Text] [PDF]

Home page
 CarcinogenesisHome page
J. Zhang, X. Jin, S. Fang, R. Wang, Y. Li, N. Wang, W. Guo, Y. Wang, D. Wen, L. Wei, et al.
The functional polymorphism in the matrix metalloproteinase-7 promoter increases susceptibility to esophageal squamous cell carcinoma, gastric cardiac adenocarcinoma and non-small cell lung carcinoma
Carcinogenesis, October 1, 2005; 26(10): 1748 - 1753.
[Abstract] [Full Text] [PDF]


HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Copyright © 2003 by the American Association for Clinical Chemistry.